The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in...

Area of Science:

• Cardiovascular Research
• Immunology
• Metabolic Disease

Background:

• Cardiovascular disease, primarily atherosclerosis, is a leading global cause of mortality.
• Atherosclerosis is an inflammatory condition of the vessel wall.
• The tryptophan metabolite 3-hydroxyanthranilic acid (3-HAA) demonstrates anti-inflammatory properties in other disease models.

Purpose of the Study:

• To investigate the unexplored role of 3-hydroxyanthranilic acid (3-HAA) in the context of atherosclerosis.
• To evaluate the therapeutic potential of 3-HAA in mitigating atherosclerosis progression.

Main Methods:

• Utilized atherosclerosis-prone Ldlr-/- mice and in vitro cell culture experiments.
• Administered 3-HAA treatment for eight weeks.
• Assessed lesion size, inflammatory markers, macrophage oxLDL uptake, and plasma lipid levels.

Main Results:

• Significant reduction in aortic lesion size observed following 3-HAA treatment.
• Modulation of local and systemic inflammatory responses by 3-HAA.
• Inhibition of oxidized low-density lipoprotein (oxLDL) uptake by macrophages, crucial for foam cell formation.
• Significant alterations in plasma cholesterol and triglyceride levels, potentially via peroxisome proliferator-activated receptor (PPAR) signaling.

Conclusions:

• 3-Hydroxyanthranilic acid (3-HAA) effectively inhibits atherosclerosis.
• 3-HAA exerts its effects by concurrently regulating key pathological components: lipid metabolism and inflammation.
• 3-HAA presents a promising therapeutic target for atherosclerosis.